<p>Amgen has shelved its once-promising psoriasis drug. Motley Fool's Michael Douglass and Todd Campbell help investors understand the impact.</p>

Amgen has shelved its once-promising psoriasis drug. Motley Fool's Michael Douglass and Todd Campbell help investors understand the impact.

Amgen Inc: Why You Shouldn't Count Chickens Before They Hatch

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Amgen Inc: Why You Shouldn't Count Chickens Before They Hatch

Sign up to save your podcasts

Amgen Inc: Why You Shouldn't Count Chickens Before They Hatch

Amgen Inc: Why You Shouldn't Count Chickens Before They Hatch

More shows like Industry Focus

Motley Fool Hidden Gems Investing

Motley Fool Answers

Rule Breaker Investing

MarketFoolery